We are at the forefront of developing new science and integrating historical treatment.

The Minder® system* is based on decades of learning, research and development primarily with and for sufferers of refractory epilepsy.

Physicians may use the system to reveal previously unseen brain activity. Follow us on LinkedIn, which is the primary place where you can connect with us, join the discussion and stay up to date with our progress.

*For investigational use only.

Together we can take more steps towards greater freedom for patients.

Follow us on LinkedIn to stay up to date

Overview of potential value for physicians.

Reveal the unseen events

Minder may be particularly effective for refractory patients. Especially to capture more data and not rely on subjective patient feedback or diaries.

Data is captured 24/7 potentially revealing:

type of seizure, duration and number
severity of condition
seizure onset location (lateralisation)
nocturnal events
analyse interictal activity (high & low frequencies)

Patient management

Potential for physicians to see the effects of medication changes as well as triggers such as:

lifestyle
sleep quality
stress
exercise
menstrual cycles

Additionally, patients may record triggers against the data for future reference

Clinical science efficacy and use

During the past 4 years, many major papers have been published (which can be found on this page), along with over 20 clinical studies.

This research is illuminating a new understanding of triggers and the predictability of seizures.

Evidence based knowledge for revealing unseen events.

Most seizures go under reported

Automated seizure detection

Seizure rhythms, forecasting & prediction

Triggers

Drug trials reasearch with Minder

Accurate knowledge of the frequency of epileptic seizures is a precondition for evaluating the efficacy of pharmacotherapy. It is a well-known fact that the information provided by epilepsy patients about the number of seizures they experience is often unreliable. In the present study, we aimed to identify predictors of a higher risk of unrecognized events. Thirty patients who underwent presurgical evaluation in a video/EEG monitoring unit were recruited. As soon as the patient became aware of a seizure, he or she completed a standardized questionnaire on the subjective perception of the seizure, which was then compared with the video/EEG findings. Of the 138 seizures recorded, 49.3% were reliably detected by the patient, whereas 44.2% went unnoticed; the remainder were incompletely or uncertainly perceived. Subjects in whom events occurred during sleep or originated in (or propagated to) the left temporal lobe had a significantly higher percentage of unrecognized events.

In 31 consecutive patients who were admitted to an epilepsy monitoring unit, we prospectively determined whether the patients were aware of having seizures.On admission, all patients stated that they knew of at least some of their seizures. Eight of 23 with classifiable epileptic seizures recognized that they were occasionally unaware of their seizures. During telemetry, following full recovery of consciousness after each seizure, we asked the patients whether they had recently had a seizure. For control purposes, we asked the patients the same question at random times. Among patients with seizures, there were no false-positive answers. Only 6 of 23 (26%) of the patients with epilepsy were always aware of their seizures, including complex partial and secondarily generalized events, and 7 of 23 (30%) were never aware of any seizures. Self-reporting of seizures was unreliable: Patients reporting the lowest baseline frequency of seizures had the highest fraction of unrecognized seizures. Seizure awareness was lowest for patients with temporal lobe foci, especially on the left side. Patients with primarily generalized epilepsy were more likely to be aware of tonic-clonic seizures than were patients with secondarily generalized partial seizures. All four patients with nonepileptic attacks believed that they always knew of their seizures, but only three of the four patients actually did always know. Unrecognized seizures are frequent and should be considered in patient management and in studies.

We are at the forefront of developing new science and integrating historical treatment.

The Minder® system* is based on decades of learning, research and development primarily with and for sufferers of refractory epilepsy.

Together we can take more steps towards greater freedom for patients.

Overview of potential value for physicians.

Reveal the unseen events

Patient management

Clinical science efficacy and use

Evidence based knowledge for revealing unseen events.

Most seizures go under reported

Automated seizure detection

Seizure rhythms, forecasting & prediction

Triggers

Drug trials reasearch with Minder

What You See Is Not What You Get

On the Topic of Accuracy of Patient Seizure Counts

When do patients forget their seizures? An electroclinical study

Patient awareness of seizures

Seizure Forecasting Using a Novel Sub-Scalp Ultra-Long Term EEG Monitoring System

Critical slowing down as a biomarker for seizure susceptibility

The dynamics of the epileptic brain reveal long-memory processes

Cycles in epilepsy

The circadian profile of epilepsy improves seizure forecasting

Interictal spikes and epileptic seizures: their relationship and underlying rhythmicity

Postictal suppression and seizure durations: A patient-specific, long-term iEEG analysis

Objective

Methods

Results

Significance

Circadian and circaseptan rhythms in human epilepsy: a retrospective cohort study

Background

Methods

Findings

Interpretation

Funding

Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study

Background

Methods

Findings

Interpretation

Funding

Human focal seizures are characterized by populations of fixed duration and interval

Objective

Methods

Results

Patient and caregiver perspectives on seizure prediction

Intrinsic excitability measures track antiepileptic drug action and uncover increasing/decreasing excitability over the wake/sleep cycle

A multi-dataset time-reversal approach to clinical trial placebo response and the relationship to natural variability in epilepsy

Purpose

Method

Results

Conclusions